A new trading day began on Monday, with 4D Molecular Therapeutics Inc (NASDAQ: FDMT) stock price down -4.94% from the previous day of trading, before settling in for the closing price of $7.09. FDMT’s price has ranged from $2.23 to $17.41 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -9.89% over the past five years. Meanwhile, its annual earnings per share averaged -23.85%. With a float of $42.62 million, this company’s outstanding shares have now reached $46.70 million.
Let’s look at the performance matrix of the company that is accounted for 227 employees.
4D Molecular Therapeutics Inc (FDMT) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of 4D Molecular Therapeutics Inc is 8.75%, while institutional ownership is 81.97%. The most recent insider transaction that took place on Sep 16 ’24, was worth 8,165. In this transaction Chief Legal Officer of this company sold 500 shares at a rate of $16.33, taking the stock ownership to the 6,781 shares.
4D Molecular Therapeutics Inc (FDMT) Performance Highlights and Predictions
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.79 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.89 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -23.85% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -9.91% during the next five years compared to -9.89% drop over the previous five years of trading.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
Here are 4D Molecular Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10491.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.71, a number that is poised to hit -1.01 in the next quarter and is forecasted to reach -3.81 in one year’s time.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
4D Molecular Therapeutics Inc (NASDAQ: FDMT) saw its 5-day average volume 0.65 million, a negative change from its year-to-date volume of 0.88 million. As of the previous 9 days, the stock’s Stochastic %D was 61.58%.
During the past 100 days, 4D Molecular Therapeutics Inc’s (FDMT) raw stochastic average was set at 84.14%, which indicates a significant increase from 62.39% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.56 in the past 14 days, which was higher than the 0.35 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.99, while its 200-day Moving Average is $4.93. Nevertheless, the first resistance level for the watch stands at $7.07 in the near term. At $7.40, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.61. If the price goes on to break the first support level at $6.53, it is likely to go to the next support level at $6.31. Assuming the price breaks the second support level, the third support level stands at $5.98.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Key Stats
With a market capitalization of 314.76 million, the company has a total of 46,702K Shares Outstanding. Currently, annual sales are 40 K while annual income is -160,870 K. The company’s previous quarter sales were 20 K while its latest quarter income was -54,660 K.
